Navigation Links
Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
Date:1/8/2009

al Scientist Training Program; Grass, Helen Hay Whitney, Alfred P. Sloan, March of Dimes, and Klingenstein Foundations and the National Institutes of Health (NIH). He has been or is currently on editorial boards for multiple scientific journals. He currently sits on scientific advisory boards for Novartis and Cellular Bioengineering, Inc.

Dr. Andrew Tager is an Assistant Professor at Harvard Medical School in the Pulmonary and Critical Care Unit of the Massachusetts General Hospital, and co-director of the hospital's interstitial lung disease program. His research is focused on understanding pulmonary inflammation, lung injury and idiopathic pulmonary fibrosis (IPF). Recently Dr. Tager's laboratory published a seminal paper demonstrating that the lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. The results suggested that lysophosphatidic acid is the chemoattractant predominantly responsible for recruiting fibroblasts into the lungs of IPF patients.

Peppi Prasit, Amira Pharmaceuticals' CSO, commented, "We are delighted to have these three renowned scientists join our advisory board. Amira has an outstanding group of scientific advisors who bring complementary skills and experience to our drug discovery and development programs."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the phospholipid pathways. Amira has a strategic partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for effi
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
2. Amira Pharmaceuticals Appoints First Vice President of Development
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
6. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... 2014 The "North ... Devices Market by Angioplasty Balloon (Plain/Old, ... OCT), IVC Filter (Retrievable), Endovascular Stent ... and studies the major market drivers, ... and Canada. , Browse 108 market ...
(Date:8/21/2014)... August 21, 2014 mynt welcomes industry ... promoters to join its growing company. Since its pre-launch ... in product sales and continues to gain momentum leading ... , Rob and Tiffanie came into network marketing by ... a number of network marketing companies. Tiffanie needed help ...
(Date:8/21/2014)... One of the emerging trends in the market ... This increases the availability and accessibility of these products to ... Ostomy Care Accessories market to grow at a ... the report, the Global Ostomy Care Accessories market is driven ... the major drivers. The number of procedures is increasing owing ...
(Date:8/21/2014)... Australian scientists say a commercially available ... been used to successfully fight mesothelioma in lab mice. ... new research. Click here to read it now. ... treated mesothelioma cells with the S. aureus ... while simultaneously stimulating a stronger anti-tumor response in healthy ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Ostomy Care Accessories Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2
... is a primary long-term complication among premature infants suffering ... risk for pulmonary hypertension and impaired growth, and ... neurological problems. ,A new study finds premature ... with inhaled nitric oxide. ,Researchers from the University ...
... have lasted for less than three months. ,A new ... exercise sheet// handouts, and telephone follow-up calls may help ... ,Researchers from Indiana University developed a self-management program for ... focuses on boosting confidence in order to increase their ...
... a step forward in their search for a cure for ... the spleen appear to develop into insulin producing //pancreatic islet ... with diabetes. ,The latest research is a follow ... advanced type 1 diabetes in mice. The new research focuses ...
... New research shows screening newborns for biochemical genetic disorders ... parents. However, researchers say false-positive screening results may increase ... genetic disorders required a separate test, but now, doctors ... just one sample of blood by using a device ...
... transplanting chimpanzee organs into humans in need of an organ ... survived 20 days. // Since then, doctors have continued to ... cells to treat various diseases, all with varying degrees of ... -- also known as xenotransplantation. ,Dick Beyer ...
... Arthritis is a common health problem worldwide. Both osteoarthritis ... patients. There is no cure for arthritis and no ... new study could help lead doctors towards a drug ... the molecular pathway and an enzyme that play a ...
Cached Medicine News:Health News:Screening Newborns Questioned 2Health News:Animals Can give us a second chance at life 2
(Date:8/21/2014)... Aug. 21, 2014  Armada Health Care (Armada), ... (GPO), is pleased to announce an agreement with ... host of innovative specialty pharmacy patient program offerings. ... therapy management services to specialty patients via Armada,s ... Aurora will use the OTM platform as ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... Pa. , Aug. 21, 2014   ... ), a specialty biopharmaceutical company, today announced positive ... of collagenase clostridium histolyticum (or CCH) for the ... as cellulite. In the Phase 2a trial, all ... and high (0.84mg)) showed an improvement in the ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... (Nasdaq: DNDN ) today announced that the ... convertible senior notes due January 15, 2016 (the "Notes") ... to purchase an additional $80 million aggregate principal amount ... exercise of the overallotment option, resulted in net proceeds ...
... Hospira, Inc. (NYSE: HSP ), the ... Food and Drug Administration (FDA) approval of Topotecan Injection, ... in the United States. The medication is a generic ... more than $140 million. Hospira,s topotecan is indicated for ...
Cached Medicine Technology:Dendreon Announces Exercise and Closing of Overallotment Option 2Hospira Announces FDA Approval of Topotecan Injection 2
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
... Endotracheal Tube Kits (silicone) Magill, ... includes a SidePort™ AutoControl™ airway connector, ... mm ISO connector., ,The wire ... helping to ensure an open airway., ...
... Portex® Blue Line® uncuffed ... Magill or Murphy styles, in ... ,Blue Line® adult and pediatric ... from implant-tested polyvinyl chloride with ...
Medicine Products: